Innate Pharma announces conference call and webcast
Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares
Innate Pharma Announces Proposed Offering of Ordinary Shares
Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer
Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma
Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference
Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)
Outcome of Innate Pharma’s 2026 Annual General Meeting
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
